# Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients

> **NCT03331601** · PHASE2 · RECRUITING · sponsor: **Universitair Ziekenhuis Brussel** · enrollment: 30 (estimated)

## Conditions studied

- Carcinoma
- Receptor, ErbB-2

## Interventions

- **DRUG:** 68GaNOTA-Anti-HER2 VHH1

## Key facts

- **NCT ID:** NCT03331601
- **Lead sponsor:** Universitair Ziekenhuis Brussel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-10-16
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03331601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03331601, "Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03331601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*